ABVC Financial Statements From 2010 to 2024

ABVC Stock  USD 0.53  0.02  3.92%   
ABVC Biopharma financial statements provide useful quarterly and yearly information to potential ABVC Biopharma investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on ABVC Biopharma financial statements helps investors assess ABVC Biopharma's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting ABVC Biopharma's valuation are summarized below:
Gross Profit
350.7 K
Market Capitalization
6.5 M
Enterprise Value Revenue
16.8846
Revenue
136.4 K
Earnings Share
(0.81)
We have found one hundred twenty available fundamental signals for ABVC Biopharma, which can be analyzed and compared to other ratios and to its rivals. Investors should ensure to validate all of ABVC Biopharma's prevailing performance against the performance from 2010 to 2024 to make sure the company is sustainable for few more years. As of December 2, 2024, Market Cap is expected to decline to about 92.8 M. In addition to that, Enterprise Value is expected to decline to about 89.8 M

ABVC Biopharma Total Revenue

157,440

Check ABVC Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ABVC Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 2.6 M, Selling General Administrative of 5 M or Total Revenue of 157.4 K, as well as many indicators such as Price To Sales Ratio of 31.34, Dividend Yield of 0.0 or PTB Ratio of 0.57. ABVC financial statements analysis is a perfect complement when working with ABVC Biopharma Valuation or Volatility modules.
  
Check out the analysis of ABVC Biopharma Correlation against competitors.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.

ABVC Biopharma Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets15.2 M14.5 M5.3 M
Slightly volatile
Short and Long Term Debt Total1.9 M2.3 M1.9 M
Slightly volatile
Total Current Liabilities6.2 M5.9 M3.4 M
Slightly volatile
Common Stock Shares Outstanding4.6 M4.3 M3.3 M
Pretty Stable
Liabilities And Stockholders Equity15.2 M14.5 M5.3 M
Slightly volatile
Non Current Liabilities Total407.7 K429.1 K833.6 K
Very volatile
Other Stockholder Equity76.9 M73.3 M29.5 M
Slightly volatile
Total Liabilities6.7 M6.4 M3.9 M
Slightly volatile
Total Current Assets1.4 M1.7 M1.6 M
Slightly volatile
Other Current Liabilities4.1 M3.9 M1.8 M
Slightly volatile
Current Deferred Revenue83.5 K79.5 K21 K
Slightly volatile
Cash57.1 K60.2 K742.6 K
Slightly volatile
Cash And Short Term Investments132.5 K139.5 K765.2 K
Slightly volatile
Common Stock7.5 K7.9 K52.6 K
Very volatile
Net Receivables625 K759.6 K441.6 K
Slightly volatile
Property Plant And Equipment Net9.2 M8.8 M1.9 M
Slightly volatile
Non Current Assets Total13.5 M12.8 M4.1 M
Slightly volatile
Property Plant And Equipment Gross12.7 M12.1 M2.3 M
Slightly volatile
Capital Stock7.5 K7.9 K136.4 K
Slightly volatile
Capital Lease Obligations920.8 K809.3 K768.9 K
Slightly volatile
Non Current Liabilities Other13.7 K21.7 K6.8 K
Slightly volatile

ABVC Biopharma Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Selling General AdministrativeMM4.3 M
Slightly volatile
Total Revenue157.4 K152.4 K190.9 K
Slightly volatile
Other Operating Expenses4.2 M8.4 M4.5 M
Slightly volatile
Cost Of Revenue317.1 K302 K76.6 K
Slightly volatile
Total Operating Expenses4.2 M8.1 M4.4 M
Slightly volatile
Depreciation And Amortization40.3 K28.5 K34.3 K
Pretty Stable
Selling And Marketing Expenses24.4 K25.7 K2.1 M
Slightly volatile
Research DevelopmentM1.1 M5.2 M
Slightly volatile
Interest Income194.8 K185.5 K47.2 K
Slightly volatile
Reconciled Depreciation26.7 K28.5 K39.4 K
Slightly volatile

ABVC Biopharma Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Total Cash From Financing Activities3.2 M3.9 M3.7 M
Slightly volatile
End Period Cash Flow875.2 K716.8 K1.1 M
Slightly volatile
Stock Based Compensation2.1 M1.6 M1.6 M
Slightly volatile
Issuance Of Capital Stock997.5 K1.1 M2.4 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio31.3432.9945819.9 K
Pretty Stable
Days Sales Outstanding1.9 K1.8 K788
Slightly volatile
Average Payables20.1 K21.2 K31.9 K
Slightly volatile
Stock Based Compensation To Revenue10.1910.73092.7 K
Pretty Stable
Capex To Depreciation0.710.74311.526
Pretty Stable
EV To Sales45.1747.5444819.6 K
Pretty Stable
Payables Turnover0.890.930.5224
Slightly volatile
Sales General And Administrative To Revenue43.6545.948947 K
Slightly volatile
Research And Ddevelopement To Revenue6.626.973150.7069
Slightly volatile
Capex To Revenue0.130.13911.1594
Slightly volatile
Cash Per Share0.03060.0322103
Slightly volatile
Days Payables Outstanding38440470.2 K
Slightly volatile
Intangibles To Total Assets0.520.850.8611
Pretty Stable
Current Ratio0.270.27930.5868
Pretty Stable
Receivables Turnover0.190.20073.7058
Slightly volatile
Graham Number9.7610.275111.9 K
Slightly volatile
Capex Per Share0.00460.004963.662
Slightly volatile
Average ReceivablesM958.1 K408.5 K
Slightly volatile
Revenue Per Share0.03690.03529.1631
Slightly volatile
Interest Debt Per Share0.870.91382.9 K
Slightly volatile
Debt To Assets0.09630.10131.6989
Slightly volatile
Days Of Payables Outstanding38440470.2 K
Slightly volatile
Ebt Per Ebit1.061.29671.5
Very volatile
Net Income Per E B T1.170.9870.9966
Very volatile
Cash Ratio0.00960.01010.396
Very volatile
Days Of Sales Outstanding1.9 K1.8 K788
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.131.0051.0148
Slightly volatile
Fixed Asset Turnover0.01650.01740.1386
Pretty Stable
Debt Ratio0.09630.10131.6989
Slightly volatile
Price Sales Ratio31.3432.9945819.9 K
Pretty Stable
Asset Turnover0.010.01050.0347
Pretty Stable

ABVC Biopharma Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap92.8 M97.7 M63.8 M
Slightly volatile
Enterprise Value89.8 M94.5 M64.5 M
Slightly volatile

ABVC Fundamental Market Drivers

Cash And Short Term Investments139.5 K

ABVC Upcoming Events

29th of March 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About ABVC Biopharma Financial Statements

ABVC Biopharma stakeholders use historical fundamental indicators, such as ABVC Biopharma's revenue or net income, to determine how well the company is positioned to perform in the future. Although ABVC Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in ABVC Biopharma's assets and liabilities are reflected in the revenues and expenses on ABVC Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ABVC Biopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue79.5 K83.5 K
Total Revenue152.4 K157.4 K
Cost Of Revenue302 K317.1 K
Stock Based Compensation To Revenue 10.73  10.19 
Sales General And Administrative To Revenue 45.95  43.65 
Research And Ddevelopement To Revenue 6.97  6.62 
Capex To Revenue 0.14  0.13 
Revenue Per Share 0.04  0.04 
Ebit Per Revenue(53.90)(56.60)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether ABVC Biopharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ABVC Biopharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Abvc Biopharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Abvc Biopharma Stock:
Check out the analysis of ABVC Biopharma Correlation against competitors.
For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.
You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.81)
Revenue Per Share
0.017
Quarterly Revenue Growth
18.175
Return On Assets
(0.45)
Return On Equity
(3.20)
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.